3Q10 sales of branded Lovenox were €184M ($258M) in Western Europe, €129M ($181M) in emerging markets, and €21M ($29M) in the rest of the non-US world, yielding total ex-US sales of €334M ($469M) (see table on page 16 of http://en.sanofi-aventis.com/binaries/20101028_Q3_2010_en_tcm28-29489.pdf ).
Despite these sizable numbers, I have doubts about the business proposition of developing an ex-US Lovenox biosimilar for the reasons mentioned in #msg-55882487.
Market Data 
Markets 
AI
